Collegium Pharmaceutical, INC Form 4 insider transactions

David Dieter, EVP & General Counsel of Collegium Pharmaceutical, received a grant of 68,449 restricted stock units (RSUs) on March 17, 2025.

Scott Dreyer, EVP & Chief Commercial Officer of Collegium Pharmaceutical, files an amended Form 4 to correct the transaction date of a sale of common stock.

Colleen Tupper, EVP & Chief Financial Officer of Collegium Pharmaceutical, sold 977 shares of common stock at a weighted average price of $30.0034 on March 14, 2025, under a pre-arranged 10b5-1 trading plan.

Scott Dreyer, EVP & Chief Commercial Officer of Collegium Pharmaceutical, sold 2,255 shares of common stock at an average price of $30.0049 per share under a pre-arranged Rule 10b5-1 trading plan.

EVP & Chief Commercial Officer of Collegium Pharmaceutical, Scott Dreyer, sold 15,387 shares of common stock at an average price of $30.004 per share on March 6, 2025, under a pre-arranged 10b5-1 trading plan.

Colleen Tupper, EVP & Chief Financial Officer of Collegium Pharmaceutical, sold 10,445 shares of common stock at a weighted average price of $30.006.

Colleen Tupper, EVP & CFO of Collegium Pharmaceutical, reports selling shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Scott Dreyer, EVP & Chief Commercial Officer of Collegium Pharmaceutical, sold shares of common stock on March 6th and 7th, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Shirley R. Kuhlmann, EVP and General Counsel of Collegium Pharmaceutical, exercised stock options and sold shares between March 4th and March 6th, 2025.

Michael Thomas Heffernan, a director at Collegium Pharmaceutical, acquired 4,820 shares of common stock as compensation for his service as interim CEO.

EVP and Chief Medical Officer of Collegium Pharmaceutical, Thomas B. Smith, reports acquisition and disposal of company stock and vesting of restricted stock units and performance share units.

EVP & Chief Commercial Officer Scott Dreyer reports acquisition and disposal of Collegium Pharmaceutical stock and derivative securities due to vesting of restricted stock units and performance share units.

Colleen Tupper, EVP & Chief Financial Officer of Collegium Pharmaceutical, reports acquisition and disposal of common stock and derivative securities.

EVP and General Counsel of Collegium Pharmaceutical, Shirley Kuhlmann, reports acquisition and disposal of company stock, including vesting of restricted stock units and performance share units, as well as shares withheld for taxes.

Director Nancy Lurker received 12,726 restricted stock units (RSUs) convertible to common stock in Collegium Pharmaceutical, Inc.

Shirley R. Kuhlmann, EVP and General Counsel of Collegium Pharmaceutical, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Collegium Pharmaceutical's CEO, Vikram Karnani, was granted stock options and restricted stock units as part of his compensation.

EVP and Chief Medical Officer of Collegium Pharmaceutical, Thomas B. Smith, sold 9,593 shares of common stock on September 13, 2024.

Shirley Kuhlmann, EVP and General Counsel of Collegium Pharmaceutical, sold shares of common stock in multiple transactions on September 5th and 6th, 2024.

Shirley R. Kuhlmann, EVP and General Counsel of Collegium Pharmaceutical, sold shares of common stock on June 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Colleen Tupper, EVP & CFO of Collegium Pharmaceutical, sold 19,710 shares of common stock at a weighted average price of $34.2145 under a pre-arranged 10b5-1 trading plan.

EVP & Chief Commercial Officer of Collegium Pharmaceutical, Scott Dreyer, exercised stock options and sold shares on May 23 and 24, 2024.

Director Gino Santini received 7,693 restricted stock units (RSUs) from Collegium Pharmaceutical, Inc. on May 16, 2024, vesting on May 16, 2025.

Director Gwen A. Melincoff of Collegium Pharmaceutical, Inc. reports the acquisition of 7,693 shares of common stock through a restricted stock unit (RSU) grant.

Director Neil F. McFarlane of Collegium Pharmaceutical, Inc. was granted 7,693 restricted stock units (RSUs) on May 16, 2024.

Director John Freund acquired 7,693 shares of Collegium Pharmaceutical through restricted stock units that vest on May 16, 2025.

Director John A. Fallon of Collegium Pharmaceutical, Inc. was granted 7,693 restricted stock units (RSUs) on May 16, 2024, according to a recent SEC filing.

Rita J. Balice-Gordon, a director at Collegium Pharmaceutical, received a grant of restricted stock units on May 16, 2024.

Director Michael Heffernan of Collegium Pharmaceutical, Inc. was granted 7,693 restricted stock units (RSUs) on May 16, 2024, which will vest on May 16, 2025.

Director Garen G. Bohlin of Collegium Pharmaceutical, Inc. exercised stock options and sold shares, while also receiving a grant of restricted stock units.